- Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of -15.5 on Day 8 (p
GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction
On 6ix: 6ix.com/news/gh-research-announces-primary-endpoint-met-phase-2b-trial-gh001-trd-demonstrating-15.5
In the deck
Story so far
Earlier from GH Research
- GH Research to Provide Update on Phase 2b Trial with GH001 in TRD
- GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents
- GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates
- GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates
- GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer
Later from GH Research
- GH Research Announces Pricing of $150 Million Public Offering
- GH Research Reports Full Year 2024 Financial Results and Provides Business Updates
- GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates
- GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting
- GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule
Follow GH Research into a list and get an email when it puts out news.
Follow GH Research